Prevalence of common blood-borne infections among imprisoned injection drug users in Mashhad, North-East of Iran

Archives of Iranian Medicine

Volumn 7, Issue 3, 2004, Pages 190-194

  Rowhani Rahbar, Ali ^a   Tabatabee Yazdi, Abbas ^a   Panahi, Mahmoud ^a  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Blood borne infections; Hepatitis; HIV AIDS; Injection drug users; Mashhad

Indexed keywords

CANNABIS; DIAMORPHINE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; OPIATE;

ARTICLE; BLOOD SAMPLING; BLOOD TRANSFUSION; CONTROLLED STUDY; DEMOGRAPHY; DISEASE TRANSMISSION; DRUG ABUSE; ENZYME LINKED IMMUNOSORBENT ASSAY; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN T CELL LEUKEMIA VIRUS 1; INFECTION RISK; IRAN; MAJOR CLINICAL STUDY; POPULATION RESEARCH; PREVALENCE; PRISONER; QUESTIONNAIRE; RISK ASSESSMENT; RISK FACTOR; SCREENING TEST; SEROPREVALENCE; SEXUAL BEHAVIOR; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; VIRUS INFECTION; WESTERN BLOTTING;

EID: 7944229034     PISSN: 10292977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Nakamura Y. The blood-borne viral infections. Rinsho Byori 1998; 46: 107-118.
2. Burattini M, Massad E, Rozman M, Azevedo R, Carvalho H. Correlation between HIV and HCV in Brazilian prisoners: evidence for parenteral transmission inside prison. Rev Saude Publica. 2000; 34: 431-436.
3. Keppler K, Stover H. Transmission of infectious diseases during imprisonment-results of a study and introduction of a model project for infection prevention in Lower Saxony [in German]. Gesundheitswesen. 1999; 61: 207-213.
4. Zhang C, Yang R, Xia X, et al. High prevalence of HIV-1 and hepatitis C virus coinfection among injection drug users in the south-eastern region of Yunnan, China. J Acquir Immune Defic Syndr. 2002; 29: 191-196.
5. Singh S, Prasad R, Mohanty A. High prevalence of sexually transmitted and blood-borne infections amongst the inmates of a district jail in northern India. Int J STD AIDS. 1999; 10: 475-478.
6. Saha MK, Chakrabarti S, Panda S, et al. Prevalence of HCV and HBV infections amongst HIV seropositive intravenous drug users and their noninjecting wives in Manipur, India. Indian J Med Res. 2000; 111: 37-9.
7. Ichimura H, Kurimura O, Tamura I, Tsukue I, Tsuchie H, Kurimura T. Prevalence of blood-borne viruses among intravenous drug users and alcoholics in Hiroshima, Japan. Int J STD AIDS. 1995; 6: 441-443.
8. UNAIDS. AIDS Epidemic Update: December 2002. Available from: URL: http://www.who.int/hiv/pub/epidemiology/epi2002/en/.
9. Ministry of Health. HIV/AIDS in Iran. The Ministry of Health, Treatment, and Medical Education of Iran, Deputy of Health; 2002.
10. Nassirimanesh B. Proceedings of the Fourth National Harm Reduction Conference, Seattle, USA; 2002. Abstract.
11. Bell J, Batey RG, Farrell GC, Crewe EB, Cunningham AL, Byth K. Hepatitis C virus in intravenous drug users. Med J Aust. 1990; 153: 274-276.
12. Girardi E, Zaccarelli M, Tossini G, Puro V, Narciso P, Visco G. Hepatitis C virus infection in intravenous drug users: prevalence and risk factors. Scand J Infect Dis. 1990; 22: 751-752.
13. Hagan H. Hepatitis C virus transmission dynamics in injection drug users. Subst Use Misuse. 1998; 33: 1197-1212.
14. Crofts N, Jolley D, Kaldor J, van Beek I, Wodak A. Epidemiology of hepatitis C virus infection among injecting drug users in Australia. J Epidemiol Community Health. 1997; 51: 692-697.
15. Garfein RS, Vlahov D, Galai N, Doherty MC, Nelson KE. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health. 1996; 86: 655-661.
16. Henrard DR, Soriano V, Robertson E, et al. Prevalence of human T-cell lymphotropic virus type 1 (HTLV-1) and HTLV-2 infections among Spanish drug users measured by HTLV-1 assay and HTLV-1 and -2 assays. HTLV-1 and HTLV-2 Spanish Study Group. J Clin Microbiol. 1995; 33: 1735-1738.
17. Tavanai-Sani A. Serologic prevalence of HTLV among blood donors in Mashhad (northeastern Iran). Arch Iranian Med. 2001; 4: 25-26.
18. Nerurkar VR, Achiron A, Song KJ, et al. Human T-cell lymphotrophic virus type I in Iranian-born Mashhadi Jews: genetic and phylogenetic evidence for common source of infection. J Med Virol. 1995; 45: 361-366.
19. Shrestha SM, Shrestha DM, Gafney TE, Maharjan KG, Tsuda F, Okamoto H. Hepatitis B and C infections among drug abusers in Nepal. Trop Gastroenterol. 1996; 17: 212-213.
20. Choopanya K, Des Jarlais DC, Vanichseni S, et al. Incarceration and risk for HIV infection among injection drug users in Bangkok. J Acquir Immune Defic Syndr. 2002; 29: 86-94.
21. Samuel MC, Doherty PM, Bulterys M, Jenison S.A. Association between heroin use, needle sharing, and tattoos received in prison with hepatitis B and C positivity among street-recruited injecting drug users in New Mexico, USA. Epidemiol Infect. 2001; 127: 475-484.
22. Stark K, Bienzle U, Vonk R, Guggenmoos-Holzmann I. History of syringe sharing in prison and risk of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus infections among injecting drug users in Berlin. Int J Epidemiol. 1997; 26: 1359-1366.
23. Stark K, Muller R, Bienzle U, Guggenmoos-Holzmann I. Frontloading: a risk factor for HIV and hepatitis C virus infection among injecting drug users in Berlin. AIDS. 1996; 10: 311-3117.
24. Pallas JR, Farinas-Alvarez C, Prieto D, Delgado-Rodriguez M. Coinfections by HIV, hepatitis B, and hepatitis C in imprisoned injecting drug users. Eur J Epidemiol. 1999; 15: 699-704.
25. Mokri A. Brief overview of the status of drug abuse in Iran. Arch Iranian Med. 2002; 5: 184-190.
26. Pallas J, Farinas-Alvarez C, Prieto D, Llorca J, Delgado-Rodriguez M. Risk factors for monoinfections and coinfections with HIV, hepatitis B, and hepatitis C viruses in northern Spanish prisoners. Epidemiol Infect. 1999; 123: 95-102.
27. Murrill CS, Weeks H, Castrucci BC, et al. Age-specific seroprevalence of HIV, hepatitis B virus, and hepatitis C virus infections among injection drug users admitted to drug treatment in 6 US cities. Am J Public Health. 2002; 92: 385-387.